Relationship Between Signaling Pathway and Diabetic Retinopathy and Intervention of Traditional Chinese Medicine： A Review
10.13422/j.cnki.syfjx.20231014
- VernacularTitle:信号通路与糖尿病视网膜病变的关系及中医药干预研究进展
- Author:
Suzhen LIU
1
;
Haodong YANG
1
;
Huazhi ZHANG
1
;
Jinning SUN
1
;
Hui LIU
1
Author Information
1. Gansu University of Chinese Medicine， Lanzhou 730000， China
- Publication Type:Journal Article
- Keywords:
traditional Chinese medicine;
diabetic retinopathy;
signaling pathways;
research progress
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(22):265-275
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy （DR） is one of the most common chronic microvascular complications of diabetes mellitus. It has a high rate of blindness， and the age of onset is gradually getting younger， which seriously affects the physical and mental health and quality of life of patients. The disease is retinal damage induced by diabetes mellitus， which is a kind of fundus disease with the main manifestations of fundus hemorrhage， hard exudation， microhemangioma， cotton-wool spots， neovascularization， etc. In traditional Chinese medicine （TCM）， it is classified into the category of "diabetic cataracts" and other diseases. At present， there is no effective method to prevent the progress of the disease in modern medicine， so it is particularly important to choose a reasonable and effective intervention to prevent and treat DR. Studies have confirmed that TCM has unique advantages in the treatment of DR. It can use its advantages of multiple bioactive components， multiple targets， and multiple pathways to intervene in the development process of DR from various aspects. By searching for the relevant literature on the progress of the intervention of DR with TCM monomers and compounds， this paper mainly reviews the relevant research results of the treatment of DR with multiple signaling pathways such as phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）， nuclear factor kappa-B（NF-κB）， p38 mitogen-activated protein kinase （p38 MAPK）， nuclear factor erythroid 2-related factor （Nrf2）/hemeoxygenase-1 （HO-1）， Hippo， advanced glycation end products （AGEs）/receptor for advanced glycation end products （RAGE）， and Akt/glycogen synthase kinase-3β （GSK-3β）， so as to provide more ideas and directions for the clinical prevention and treatment of DR.
